Press Release
Awakn Life Sciences Corp.
AWKNF the biotech company developing psychedelic therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) shared its recent corporate news.
Dr. Ben Sessa has resigned from his role as Head of Psychedelic Medicine and will transfer his 49% stake of Awakn Bristol Ltd. to the company’s wholly-owned subsidiary Awakn Life Sciences Inc., which will consequently hold a 100% interest in the Bristol operation.
Awakn has filed three Patent Cooperation Treaty (PCT) applications for its New Chemical Entity (NCE) program. As a result and pursuant to an amendment to a March 2021 IP transfer agreement between Awakn Life Sciences Inc. and Equasy Enterprises Ltd., an additional 70,000 Awakn common shares are issuable to Prof. David Nutt.
